The reimbursement listing process for ‘Columvi,' the first bispecific antibody treatment option for lymphoma, will begin in Korea.

According to Dailypharm coverage, Roche Korea's CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) is expected to be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee meeting on the 10th.

Columvi was approved in Korea last December for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy.

The drug is a third-line treatment option for DLBCL, like Novartis’s chim